MaxCyte, Inc. Notice of Full Year Results (0875Y)
March 01 2017 - 2:01AM
UK Regulatory
TIDMMXCT
RNS Number : 0875Y
MaxCyte, Inc.
01 March 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Full Year Results
Maryland, USA - 1 March 2017: MaxCyte (LSE: MXCT), a US-based
global company dedicated to accelerating the discovery,
development, manufacturing and commercialization of
next-generation, cell-based medicines, will be announcing its full
year audited results for the year ended 31 December 2016 on Monday
20 March 2017.
Doug Doerfler, Chief Executive Officer, will host a presentation
and live conference call for analysts at 11.00am GMT on the day of
the results at the offices of Consilium Strategic Communications,
41 Lothbury, London, EC2R 7HG.
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte (LSE: MXCT), is a US-based global company dedicated to
accelerating the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
platform to biopharmaceutical partners engaged in drug discovery
and development, biomanufacturing, and cell therapy, including gene
editing and immuno-oncology. With its robust delivery platform,
MaxCyte's team of scientific experts helps its partners to unlock
their product potential and solve development and commercialization
challenges. This platform allows for the engineering of nearly all
cell types, including human primary cells, with any molecule, at
any scale. It also provides unparalleled consistency and minimal
cell disturbance, thereby facilitating rapid, large-scale, clinical
and commercial grade high-performance cell engineering in a
non-viral system and with low-toxicity concerns. The Company's
cell-engineering platform is CE-marked and FDA-accredited,
providing MaxCyte's customers and partners with an established
regulatory path to commercialize cell-based medicines.
MaxCyte is also developing CARMA, its proprietary, breakthrough
platform in immuno-oncology, to rapidly manufacture CAR therapies
for a broad range of cancer indications, including solid tumors
where existing CAR-T approaches face significant challenges.
For more information, visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORTPMJTMBJTBIR
(END) Dow Jones Newswires
March 01, 2017 02:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024